×
ADVERTISEMENT

JUNE 18, 2025

FDA Approves Yeztugo for HIV PrEP Lasting 6 Months


Originally published by our sister publication Infectious Disease Special Edition

By IDSE News Staf

The FDA approved lenacapavir (Yeztugo, Gilead Sciences), an injectable HIV-1 capsid inhibitor, to be used as pre-exposure prophylaxis (PrEP) to reduce the risk for sexually acquired HIV in adults and adolescents weighing at least 35 kg, making it the first and only twice-yearly option for Americans who need or want PrEP.

SameSexCouple_thumb.jpg

Data show that almost 100% of participants who received lenacapavir in the